

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

MNNG/HOS CI #5

RRID:CVCL_0439

Type: Cell Line

Proper Citation

RRID:CVCL_0439

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0439

Proper Citation: RRID:CVCL_0439

Description: Cell line MNNG/HOS CI #5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Osteosarcoma

Defining Citation: [PMID:265298](#), [PMID:833871](#), [PMID:1385192](#), [PMID:2823272](#), [PMID:2978869](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6254071](#), [PMID:6269117](#), [PMID:6575958](#), [PMID:6590967](#), [PMID:7873286](#), [PMID:12645653](#), [PMID:19787792](#), [PMID:21519327](#), [PMID:22282976](#), [PMID:23144859](#), [PMID:24136885](#), [PMID:26320182](#), [PMID:28196595](#), [PMID:29334376](#)

Comments: Anecdotal: Cell line where the MET (MNNG-HOS transforming) oncogene was first identified (PubMed=6590967)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MNNG/HOS CI #5

Synonyms: MNNG/HOS, MNNG-HOS, MNNG HOS, HOS-MNNG, HOS/MNNG, MNNGHOS, MNNG-HOS (CI#5), MNNG/HOS Clone F-5, MNNG, R-1059-D, TE85, Te85, TE-85, HOS-TE85, Hos TE-85, HOS TE 85, HOS TE85, HOS (TE85), HOS(TE85), HOS (TE85, Clone F5), MNNG-HOS (TE 85, clone F-5), TE-85 clone F-5, HOS-Te85, TE 85.T, TE 85 CIF-5, HOS-TE85 clone 5, TE-85 clone 5

Cross References: BTO:BTO_0005416, CLO:CLO_0003796, CLO:CLO_0007813, CLO:CLO_0007814, EFO:EFO_0002866, MCCL:MCC:0000334, CLDB:cl1703, CLDB:cl1704, CLDB:cl1705, CLDB:cl3510, ATCC:CRL-1547, ATCC:CRL-7734, ATCC:CRL-7735, cancercellines:CVCL_0439, CCRID:3101HUMTCHu167, CCRID:5301HUM-KCB16037YJ, ChEMBL-Cells:ChEMBL3307282, ChEMBL-Targets:ChEMBL614038, CLS:300289, Cosmic:1044084, Cosmic:1074402, Cosmic:1529901, Cosmic:2301584, ECACC:87070201, GEO:GSM879219, GEO:GSM1915008, GEO:GSM1915009, GEO:GSM1915010, GEO:GSM1915011, GEO:GSM1915025, GEO:GSM1915026, GEO:GSM1915027, GEO:GSM1915028, GEO:GSM1915029, GEO:GSM2635307, GEO:GSM2635308, IARC_TP53:25022, KCB:KCB_2016037YJ, KCLB:21543, Progenetix:CVCL_0439, PubChem_Cell_line:CVCL_0439, Wikidata:Q54906271

ID: CVCL_0439

Hierarchy: cvcl_0312

Record Creation Time: 20220427T220816+0000

Record Last Update: 20260905T181201+0000

Ratings and Alerts

No rating or validation information has been found for MNNG/HOS Cl #5.

Warning: Discontinued: ATCC; CRL-7735

Anecdotal: Cell line where the MET (MNNG-HOS transforming) oncogene was first identified (PubMed=6590967)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project. **Warning:** Discontinued: ATCC; CRL-7734

Anecdotal: Cell line where the MET (MNNG-HOS transforming) oncogene was first identified (PubMed=6590967)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Li H, et al. (2026) Tumor Extracellular Vesicles IncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via m6A-Dependent hnRNPA2B1/COX-2 Axis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e19490.

Ren Z, et al. (2026) MAT2A enhances PARN transcription via SRF to accelerate glycolysis and drive malignant progression in osteosarcoma. *Communications biology*, 9(1), 241.

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. *Cancer research*, 86(9), 2161.

Wang J, et al. (2026) Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. *Science progress*, 109(2), 368504261464856.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. *Cell reports. Medicine*, 6(3), 101977.

Ucci A, et al. (2025) Human osteosarcoma cell secretome impairs neonatal mouse calvarial osteogenic cells functions and modifies the nanoparticles-derived protein profile. *Life sciences*, 379, 123837.

Jing D, et al. (2025) Transketolase promotes osteosarcoma progression through the YY1-PAK4 axis. *The FEBS journal*, 292(7), 1798.

Ren J, et al. (2024) Augmented drug resistance of osteosarcoma cells within decalcified bone matrix scaffold: The role of glutamine metabolism. *International journal of cancer*, 154(9), 1626.

Zheng J, et al. (2024) Tumor mitochondrial oxidative phosphorylation stimulated by the nuclear receptor ROR γ represents an effective therapeutic opportunity in osteosarcoma. *Cell reports. Medicine*, 5(5), 101519.

Takemoto A, et al. (2022) Targeting Podoplanin for the Treatment of Osteosarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(12), 2633.

Li HB, et al. (2022) METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma. *EBioMedicine*, 82, 104142.

Ponzetti M, et al. (2022) Effects of osteoblast-derived extracellular vesicles on aggressiveness, redox status and mitochondrial bioenergetics of MNNG/HOS osteosarcoma cells. *Frontiers in oncology*, 12, 983254.

Tang W, et al. (2022) Vascular Niche Facilitates Acquired Drug Resistance to c-Met Inhibitor in Originally Sensitive Osteosarcoma Cells. *Cancers*, 14(24).

Rathore R, et al. (2021) Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. *Cell reports*, 34(4), 108678.

Klangjorhor J, et al. (2020) Mycophenolic acid is a drug with the potential to be repurposed for suppressing tumor growth and metastasis in osteosarcoma treatment. *International journal of cancer*, 146(12), 3397.

Bernardini G, et al. (2018) Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma. *Journal of cellular physiology*, 233(6), 4961.